Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05524935 · ClinicalTrials.gov registry record · Phase 2
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
A Phase 2 study of Uveal Melanoma and Ocular Melanoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT05524935: Recruiting Phase 2 study of Uveal Melanoma and Ocular Melanoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT05524935 is a Phase 2 study of Uveal Melanoma and Ocular Melanoma that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 37 participants, below the 144-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05524935, a Phase 2 study of Uveal Melanoma and Ocular Melanoma, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective phase II multi-center trial of the combination of the PARP inhibitor olaparib with the immune checkpoint inhibitor pembrolizumab in advanced uveal melanoma.
Primary Outcome
Overall Response Rate is defined as the rate of the best overall response as complete response (CR) +partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Olaparib
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2022-10-11 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT05524935 shows while recruiting
NCT05524935 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 144-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Uveal Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05524935 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05524935 about?
NCT05524935 is a clinical study titled "Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma". This is a prospective phase II multi-center trial of the combination of the PARP inhibitor olaparib with the immune checkpoint inhibitor pembrolizumab in advanced uveal melanoma.
What is the current status of trial NCT05524935?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2022-10-11. Estimated completion is 2027-12.
What conditions does trial NCT05524935 study?
This clinical trial studies the following conditions: Uveal Melanoma, Ocular Melanoma.
What interventions are being tested in trial NCT05524935?
The interventions under investigation include: Pembrolizumab (DRUG), Olaparib (DRUG).
Who is sponsoring clinical trial NCT05524935?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05524935 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05524935's enrollment target sits among peer trials
37 19th of 29 higher than 10 of 29 other Uveal Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uveal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Adjuvant Quisinostat in High-Risk Uveal Melanoma
RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
-
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI